Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results

• Published in: Journal of clinical oncology Vol. 30; no. 15_suppl; p. 8508
• Main Authors: Hamid, Omid, Hwu, Wen-Jen, Richards, Jon M., Weber, Jeffrey S., Wolchok, Jedd D., Sznol, Mario, Minor, David R., Pavlick, Anna C., Urba, Walter John, Hodi, F. Stephen, Yang, Arvin, Michener, Tracy, Balogh, Agnes, McDermott, David F.
• Format: Journal Article
• Language: English
• Published: 20.05.2012

Abstract only 8508 Background: The EAP (CA184-045), begun in 8/07, currently provides the largest safety database for Ipi outside of controlled clinical trials (CCTs) and included pts with brain metastases (BM) and primary ocular (OM) and mucosal (MM) melanoma. The EAP was amended in 10/08 to admini...